<img alt="" height="1" width="1" />Lexicon Prices Heavily Dilutive Stock Sale At 19% DiscountWall Street Journal... Lexicon has three other drug candidates in Phase II clinical trials, including treatments for rheumatoid arthritis and irritable bowel syndrome.Lexicon Announces Pricing of Common Stock in Public Offering<nobr>PR Newswire (press release)</nobr><nobr>all 17 news articles »</nobr> |